

Financial news for HPTX dated on 2015-04-09: Extreme Networks, Citrix And AngioDynamics Lead Thursday's After-Hours Movers

Financial news for HPTX dated on 2015-03-31: Cantor Fitzgerald Downgrades Hyperion After Acquisition

Financial news for HPTX dated on 2015-03-31: Horizon Pharma Shares Rise 3% Premarket Following Several Analyst PT Increases

Financial news for HPTX dated on 2015-03-31: Needham Downgrades Hyperion Therapeutics to Hold

Financial news for HPTX dated on 2015-03-31: Cantor Fitzgerald Downgrades Hyperion Therapeutics to Hold

Financial news for HPTX dated on 2015-03-30: Benzinga's M&A Chatter for Monday March 30, 2015

Financial news for HPTX dated on 2015-03-30: Brean Capital Downgrades Hyperion Therapeutics to Hold

Financial news for HPTX dated on 2015-03-30: Benzinga's Volume Movers

Financial news for HPTX dated on 2015-03-30: Stocks Hitting 52-Week Highs

Financial news for HPTX dated on 2015-03-30: Monday's Merger Mania

Financial news for HPTX dated on 2015-03-30: Morning Market Gainers

Financial news for HPTX dated on 2015-03-30: Benzinga's Top #PreMarket Gainers

Financial news for HPTX dated on 2015-02-17: US Stock Futures Mixed Ahead Of Housing-Market Report

Financial news for HPTX dated on 2015-02-17: Hyperion Therapeutics Enters Into Completion of Phase III Clinical Trial, Option and Mutual Release Agreement With Clal Biotechnology, Yeda R&D

Financial news for HPTX dated on 2015-02-10: Hyperion Initiates Clinical Study to Further Evaluate RAVICTI in Pediatric Subjects Under 2 With Urea Cycle Disorders

Financial news for HPTX dated on 2015-01-12: Hyperion Therapeutics Announces Data Published In Genetics In Medicine

Financial news for HPTX dated on 2014-12-29: Brean Capital Initiates Coverage on Hyperion Therapeutics at Buy, Announces \$40.00 PT

Financial news for HPTX dated on 2014-12-02: Wedbush Initiates Coverage on Hyperion Therapeutics, Inc. at Outperform, Announces \$33.00 PT

Financial news for HPTX dated on 2014-11-17: Events for the Week of Nov. 17-21, 2014

Financial news for HPTX dated on 2014-11-13: The Top 25 Analysts On Wall Street

Financial news for HPTX dated on 2014-10-07: Hyperion Therapeutics, Clal Biotechnology Industries Enter into Interim Agreement in Attempt to Resolve Disputes

Financial news for HPTX dated on 2014-09-09: UPDATE: JMP Securities Reiterates On Hyperion Therapeutics Inc As Diabetes Program Is Discarded

Financial news for HPTX dated on 2014-09-09: JMP Securities Maintains Market Outperform on Hyperion Therapeutics, Inc., Lowers PT to \$35.00

Financial news for HPTX dated on 2014-09-08: Markets Close Lower Ahead Of Apple Announcement

Financial news for HPTX dated on 2014-09-08: Ford Drops On Morgan Stanley Downgrade; Multimedia Games Shares Jump

Financial news for HPTX dated on 2014-09-08: Markets Mixed; Campbell Soup Issues Weak Profit Forecast

Financial news for HPTX dated on 2014-09-08: Morning Market Losers

Financial news for HPTX dated on 2014-09-08: Hyperion Shares Now Down 20% Following Resumption of Trade After Announcing Termination of DiaPep277 Program

Financial news for HPTX dated on 2014-09-08: Hyperion Therapeutics Shares to Resume Trade at 8:30 a.m. EDT

Financial news for HPTX dated on 2014-09-08: Hyperion Therapeutics Reports Termination of DiaPep277(R) Program, Discovers Serious Misconduct by Andromeda Biotech, Expecting \$25-55M Impairment Charge

Financial news for HPTX dated on 2014-09-08: Hyperion Therapeutics Shares Halted News Pending

Financial news for HPTX dated on 2014-08-07: Hyperion Reports Q2 EPS \$0.98, May Not Compare. Revenue \$37.1M

Financial news for HPTX dated on 2014-06-25: UPDATE: Hyperion Therapeutics Announces EMA Acceptance For Review of Marketing Authorization Application For RAVICTI

Financial news for HPTX dated on 2014-06-25: Hyperion Therapeutics Announces EMA Acceptance For Review of Marketing Authorization Application For RAVICTI

Financial news for HPTX dated on 2014-06-17: Events Scheduled for Week of Jun. 16th to Jun. 20th

Financial news for HPTX dated on 2014-05-06: Hyperion Therapeutics, Inc. Reports Q1 EPS of \$0.06 vs \$0.00 Est; Revenue of \$19.50M vs \$17.76M Est

Financial news for HPTX dated on 2014-04-24: Hyperion Therapeutics to Acquire Andromeda Biotech in Cash, Stock Deal, Plus Milestone Payments

Financial news for HPTX dated on 2014-03-18: Form 8-K from Hyperion Therapeutics Shows Co. Received Notice of Paragraph IV Certification from Par Pharma on Mar. 17th, 2014

Financial news for HPTX dated on 2014-03-18: Cantor Fitzgerald Initiates Coverage on Hyperion Therapeutics, Inc. at Buy, Announces \$40.00 PT

Financial news for HPTX dated on 2014-03-10: FDA Shows Hyperion Therapeutics' Ravicti Receives Paragraph IV Challenge

Financial news for HPTX dated on 2014-02-27: Hyperion Therapeutics, Inc. Reports Q4 EPS of \$0.19; Revenue of \$18.60M vs \$15.90M Est

Financial news for HPTX dated on 2013-11-12: Hyperion Therapeutics, Inc. Reports Q3 EPS of \$0.15 vs \$(0.06) Est; Revenue of \$15.50M vs \$12.93M Est

Financial news for HPTX dated on 2013-10-01: Hyperion Therapeutics Grants Rights to Sobi to Distribute RAVICTI in Middle East

Financial news for HPTX dated on 2013-08-14: Hyperion Therapeutics, Inc. Reports Q2 EPS of \$(0.22) vs \$(0.17) Est; Revenue of \$7.30M vs \$2.17M Est

Financial news for HPTX dated on 2013-07-17: Hyperion Therapeutics Announces Ashley Gould as Chief Legal Officer

Financial news for HPTX dated on 2013-06-03: Hyperion Therapeutics Buys Worldwide Rights to BUPHENYL

Financial news for HPTX dated on 2013-05-21: Benzinga's Top Pre-Market Losers

Financial news for HPTX dated on 2013-05-09: Hyperion Therapeutics, Inc. Reports Q1 EPS of \$(0.52) vs \$(0.58) Est; Revenue of \$783.0K vs \$270.0K Est

Financial news for HPTX dated on 2013-04-08: Benzinga's Top Initiations

Financial news for HPTX dated on 2013-04-08: JMP Securities Initiates Coverage on Hyperion Therapeutics, Inc. at Market Outperform, Announces \$30.00 PT

Financial news for HPTX dated on 2013-03-13: Hyperion Therapeutics Closes Follow-On Offering, Underwriters' Exercised Option

Financial news for HPTX dated on 2013-02-26: Hyperion Therapeutics Files to Offer Up to \$50M in Common Stock

Financial news for HPTX dated on 2013-02-25: Hyperion Therapeutics, Inc. Reports Q4 EPS of \$(0.50) vs \$(0.38) Est

Financial news for HPTX dated on 2013-02-01: Hyperion Therapeutics Resumes Trading

Financial news for HPTX dated on 2013-02-01: Hyperion Therapeutics Resumes Trading

Financial news for HPTX dated on 2013-02-01: Hyperion Therapeutics Shares Resume Trading, Falling Into Negative Territory

Financial news for HPTX dated on 2013-02-01: Hyperion Therapeutics Resumes Trading

Financial news for HPTX dated on 2013-02-01: Hyperion Therapeutics to Resume Trade at 3:20PM EST

Financial news for HPTX dated on 2013-02-01: Hyperion Confirms FDA Approval for RAVICITI

Financial news for HPTX dated on 2013-02-01: Hyperion Shares Halted Following News of FDA Approval for Raviciti, a Drug for the Chronic Management of Some Urea, Stock Halted Up 3%

Financial news for HPTX dated on 2013-02-01: Hyperion Therapeutics Halted News Pending

Financial news for HPTX dated on 2013-01-16: Mid-Day Market Movers

Financial news for HPTX dated on 2013-01-16: Hyperion Therapeutics Shares Resume Trading Down 8.5%

Financial news for HPTX dated on 2013-01-16: Hyperion Therapeutics Shares to Resume Trade at 9:15AM EST

Financial news for HPTX dated on 2013-01-16: Hyperion Therapeutics Shares to Resume Trade at 9:15AM EST

Financial news for HPTX dated on 2013-01-16: FDA Will Not Meet PDUFA Date for Hyperion's Ravicti

Financial news for HPTX dated on 2013-01-16: Hyperion Therapeutics Halted News Pending

Financial news for HPTX dated on 2012-11-12: HALT-HE Study Underscores Role of Ammonia in Hepatic Encephalopathy; Reports Phase 2 Study Results

Financial news for HPTX dated on 2012-09-05: Hyperion Therapeutics Announces Extension of Action Date for Ravicti(TM) NDA to January 23, 2013

Financial news for HPTX dated on 2012-08-28: Hyperion Therapeutics Appoints Daniel Welch to Board of Directors

Financial news for HPTX dated on 2012-08-20: Cowen Initiates Coverage Hyperion Therapeutics at Outperform

Financial news for HPTX dated on 2012-08-20: Leerink Swan Initiates Coverage Hyperion Therapeutics at Outperform

Financial news for HPTX dated on 2012-08-20: Benzinga's Top Initiations

Financial news for HPTX dated on 2012-07-26: Hyperion Opens Trading at \$10.50, Originally Priced at \$10

Financial news for HPTX dated on 2012-07-26: Hyperion Therapeutics Announces Pricing of 5M Share Initial Public Offering at \$10.00